Disease landscape

Non-Hodgkin Lymphoma clinical trials

Get alerts when Non-Hodgkin Lymphoma trials change

1,136 active trials 642 recruiting 83 Phase 3 486 sponsors 109 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 42 of 109 changes on 20 trials

2026-08-14
Recruitment suspended
Recruitment suspended: Accrual Goal Met
NCT04930653 Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic… · City of Hope Medical Center · Phase 2
2026-08-26
Primary completion pushed: 2026-07 → 2026-11
Enrollment reduced: 39 → 21 participants
Completion pushed: 2026-07 → 2026-11
NCT06079164 Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma · Kite, A Gilead Company · Phase 1
2026-08-29
Primary completion pushed: 2027-09-01 → 2028-09-01
Completion pushed: 2027-09-01 → 2028-09-01
NCT06649812 Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With… · National Cancer Institute (NCI) · Phase 2
2026-08-14
Primary completion pushed: 2027-11-24 → 2028-04-21
NCT06526793 Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R)… · AstraZeneca · Phase 2
2026-09-02
Primary completion pushed: 2026-08-05 → 2027-07-06
Completion pushed: 2026-08-05 → 2027-07-06
NCT01961063 Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related… · City of Hope Medical Center · Phase 1
2026-08-29
Primary completion pushed: 2027-07-31 → 2028-07-31
Completion pushed: 2029-07-31 → 2030-07-31
NCT06687772 CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based… · Washington University School of Medicine · Phase 2
2026-09-01
Primary endpoint(s) modified
Recruitment opened
Trial sites expanded: 0 → 6 locations
Completion pushed: 2032-06 → 2033-08
NCT07516093 Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL · Nurix Therapeutics, Inc. · Phase 3
2026-08-28
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2026-07 → 2027-07
NCT04464200 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · Memorial Sloan Kettering Cancer Center · Phase 1
2026-08-28
Primary completion pushed: 2026-07 → 2026-11
Completion pushed: 2026-07 → 2026-11
NCT06383338 A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent &… · Murdoch Childrens Research Institute · Phase 1
2026-08-08
Primary completion pushed: 2026-08-31 → 2030-08-31
Completion pushed: 2026-08-31 → 2030-08-31
NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-08
Primary completion pushed: 2026-06-30 → 2027-06-30
Completion pushed: 2028-06-30 → 2029-06-30
NCT06486051 A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell… · Malaghan Institute of Medical Research · Phase 2
2026-08-07
Primary completion pushed: 2026-08-31 → 2028-08-31
Completion pushed: 2026-08-31 → 2028-08-31
NCT02861417 Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating… · M.D. Anderson Cancer Center · Phase 2
2026-08-22
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2027-05 → 2028-05
NCT06227026 Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the… · University of Utah · Phase 1
2026-08-21
Primary completion pushed: 2026-08-01 → 2027-08-01
Completion pushed: 2027-08-01 → 2028-08-01
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or… · Jonsson Comprehensive Cancer Center · Phase 1
2026-08-07
Primary completion pushed: 2026-07 → 2028-07
Completion pushed: 2027-07 → 2030-07
NCT05990465 LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell… · Medical College of Wisconsin · Phase 1
2026-08-15
Primary completion pushed: 2026-06-30 → 2027-05-25
Completion pushed: 2026-06-30 → 2027-05-25
NCT04537871 Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study · City of Hope Medical Center
2026-08-22
Primary endpoint(s) modified
NCT05006716 A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With… · BeOne Medicines · Phase 1/2
2026-08-14
Primary endpoint(s) modified
Enrollment increased: 30 → 40 participants
Trial arms changed: 1 → 2
NCT06811272 Outpatient Epcoritamab in Large B-cell Lymphoma · Massachusetts General Hospital · Phase 2
2026-08-12
Primary endpoint(s) modified
Completion pushed: 2025-11 → 2029-06
NCT03505762 Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell… · Wake Forest University Health Sciences · Phase 2
2026-08-21
Enrollment reduced: 25 → 2 participants
Enrollment closed, study ongoing
NCT06756308 A Study of Enasidenib in People With T-Cell Lymphoma · Memorial Sloan Kettering Cancer Center · Phase 2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-28 NCT07793006 New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease Indiana University new
2026-08-13 NCT07763210 Lazarus: IT Therapy for ICANS Vanderbilt-Ingram Cancer Center new Phase 2
2026-08-06 NCT07750886 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin… Natera, Inc. new
2026-08-05 NCT07748364 Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Joshua Brody new Phase 2
2026-07-28 NCT07730515 Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated… Evopoint Biosciences Inc. new Phase 1/2
2026-07-10 NCT07695896 Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin… Yanyan Liu new
2026-07-09 NCT07691606 A Study of ARC-02 in B-cell NHL Taiho Oncology, Inc. new Phase 1
2026-07-01 NCT07679919 BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies Luminary Therapeutics new Phase 1
2026-06-22 NCT07658352 A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Shanghai Helioson Pharmaceutical Co., Ltd. new Phase 1/2
2026-06-22 NCT07661537 A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma Suzhou Suncadia Biopharmaceuticals Co., Ltd. new Phase 1

Active trials by phase

Early Phase 1
37
Phase 1
269
Phase 1/2
179
Phase 2
352
Phase 2/3
16
Phase 3
67
Phase 4
12
Not charted: 204 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 1,136

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT06876649 A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Eli Lilly and Company Recruiting 2026-03-02
NCT06876662 A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic… Eli Lilly and Company Recruiting 2026-03-02
NCT07270835 Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma The First Affiliated Hospital of Soochow University Recruiting 2025-12-08
NCT07016165 Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in… Gadjah Mada University Recruiting 2025-08-22
NCT05806580 Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma Ruijin Hospital Recruiting 2024-10-23
NCT05518383 B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting 2022-08-26
NCT07760610 Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After… The First Hospital of Jilin University Not Yet Recruiting 2026-08-12
NCT06285370 A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis… Kyowa Kirin China Pharmaceutical Co., Ltd. Active, Not Recruiting 2025-09-18
NCT07046182 Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of… Zhengzhou University Active, Not Recruiting 2025-07-01
NCT06956092 Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma Zhengzhou University Not Yet Recruiting 2025-05-02
NCT06665737 Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's… Department of Medical Services Ministry of Public Health of Thailand Not Yet Recruiting 2025-01-28
NCT05814848 A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or… Changhai Hospital Not Yet Recruiting 2023-06-15
Phase 3
NCT07479797 Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants… Kite, A Gilead Company Recruiting 2026-09-04
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus… Merck Sharp & Dohme LLC Recruiting 2026-09-03
NCT07516093 Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL Nurix Therapeutics, Inc. Recruiting 2026-08-31
NCT06091865 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it… Regeneron Pharmaceuticals Recruiting 2026-08-20
NCT06724237 Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells… Eastern Cooperative Oncology Group Recruiting 2026-08-19
NCT06742996 A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared… BeOne Medicines Recruiting 2026-08-19
NCT06792253 Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory… BeBetter Med Inc Recruiting 2026-08-19
NCT07570823 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and… Sinocelltech Ltd. Recruiting 2026-08-13
NCT07678229 BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in… Rong Tao Recruiting 2026-08-13
NCT07739654 Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. King Edward Medical University Recruiting 2026-08-10
NCT07188558 A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy Lyell Immunopharma, Inc. Recruiting 2026-08-04
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) Janssen Research & Development, LLC Recruiting 2026-07-31
NCT05645107 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT)… Grifols Therapeutics LLC Recruiting 2026-07-29
See all 1,136 active Non-Hodgkin Lymphoma trials with filters →

Top sponsors by active trials in this area

Ruijin Hospital (49) · National Cancer Institute (NCI) (44) · City of Hope Medical Center (33) · Sun Yat-sen University (24) · M.D. Anderson Cancer Center (23) · Memorial Sloan Kettering Cancer Center (23) · Institute of Hematology & Blood Diseases Hospital, China (17) · The First Affiliated Hospital with Nanjing Medical University (14) · The First Affiliated Hospital of Soochow University (13) · Fondazione Italiana Linfomi - ETS (12)

Get alerts when Non-Hodgkin Lymphoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free